Genipin Enhances the Therapeutic Effects of Oxaliplatin by Upregulating BIM in Colorectal Cancer
- Kim, Bo Ram; Jeong, Yoon A.; Jo, Min Jee; Park, Seong Hye; Na, Yoo Jin; Kim, Jung Lim; Jeong, So yeon; Yun, Hye Kyeong; Kang, Sanghee; Lee, Dae Hee; Oh, Sang Cheul
- Issue Date
- American Association for Cancer Research
- Molecular Cancer Therapeutics, v.18, no.4, pp.751 - 761
- Journal Title
- Molecular Cancer Therapeutics
- Start Page
- End Page
- Despite an increase in the survival rate of patients with cancer owing to the use of current chemotherapeutic agents, adverse effects of cancer therapies remain a concern. Combination therapies have been developed to increase efficacy, reduce adverse effects, and overcome drug resistance. Genipin is a natural product derived from Gardenia jasminoides, which has been associated with anti-inflammatory, anti-angiogenic, and anti-proliferative effects; hypertension; and anti-ischemic brain injuries. However, the enhancement of oxaliplatin sensitivity by genipin remains unexplored. Our study showed that a combination of genipin and oxaliplatin exerts synergistic antitumor effects in vitro and in vivo in colorectal cancer cell lines through the reactive oxygen species (ROS)/endoplasmic reticulum (ER) stress/BIM pathway. Importantly, the combination did not affect normal colon cells. BIM knockdown markedly inhibited apoptosis induced by the combination. In addition, genipin induced ROS by inhibiting superoxide dismutase 3 activity. These findings suggest that genipin maybe a novel agent for increasing the sensitivity of oxaliplatin against colorectal cancer. The combination of oxaliplatin and genipin hold significant therapeutic potential with minimal adverse effects.
- Files in This Item
- There are no files associated with this item.
- Appears in
- 2. Clinical Science > Department of Medical Oncology and Hematology > 1. Journal Articles
- 3. Graduate School > Graduate School > 1. Journal Articles
- 2. Clinical Science > Department of Colon and Rectal Surgery > 1. Journal Articles
- 4. Research institute > Institute of Convergence New Drug Development > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.